Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

Core Viewpoint - Gilead Sciences is set to acquire Arcellx for up to $7.8 billion, marking its largest deal since 2020, aimed at enhancing its cancer treatment portfolio [1] Group 1: Acquisition Details - Gilead will pay $115 per share in cash, representing a 79% premium over Arcellx's last closing price [1] - The total acquisition cost could reach $7.8 billion, which includes an additional $5 per share contingent on achieving $6 billion in cumulative global net sales of anito-cel by the end of 2029 [1] Group 2: Strategic Rationale - The acquisition is part of Gilead's strategy to diversify its offerings beyond its core HIV and liver disease treatments, especially as it faces declining sales from its COVID-19 drug Veklury and impending patent expirations [1] - Gilead's CEO highlighted that anito-cel could become a foundational treatment for multiple myeloma, with potential for earlier lines of therapy [1] Group 3: Product and Market Impact - Anito-cel, an experimental CAR-T therapy for multiple myeloma, is currently under FDA review, with a decision expected by December 23, 2023 [1] - The acquisition is anticipated to be accretive to Gilead's earnings per share starting in 2028, contingent on FDA approval of anito-cel [1]